CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND ...

Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase 2b study (NCT05281328), evaluating efficacy and safety of ...